Skip to main content

Table 1 Cost benefit and cost-effectiveness analysis of infant hepatitis B vaccine and PMTCT, compared to no intervention

From: Impact of the national hepatitis B immunization program in China: a modeling study

Strategy

Cost (USD)

QALYs

Benefit

NB

BCR

Immunization

Infection

Total

Status quo

       

 Infant hepatitis B vaccine

52.17

1208.61

1260.78

23.88

11,968.42

11,916.25

9.49

 PMTCT

76.37

893.52

969.89

23.92

12,283.50

12,207.14

12.66

Comparison scenario

       

 Without any interventions

0

13,177.03

13,177.03

22.34

  1. Note: All costs were adjusted with respect to the cost of dollar according to the exchange rate in 2018
  2. USD US dollar, QALY quality-adjusted life year, NB net benefit, BCR benefit–cost ratio, PMTCT the prevention of mother-to-children transmission